Switzerland: Auven sells ADCT shares in underwritten offering

NYSE listed, Lausanne-based ADC Therapeutics (ADCT), a commercial-stage biotech focused on its next-generation, targeted antibody drug conjugates (ADCs), has priced an underwritten offering of 12 million of its common shares currently owned by AT Holdings II, an affiliate of Auven Therapeutics Holdings, at US$5.00 per share (before underwriting discounts and commissions). ADCT is not selling…

You must be a HMI Subscriber to view this content.

Subscribe Now »